SONM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
16.2M
0
Cost of Revenue
0
0
0
-100.0%
14.4M
0
Gross Profit
0
0
1.8M
0
Operating Expenses
1.3M
-64.7%
3.6M
5.8M
+294.0%
1.5M
R&D
0
0
181.0K
0
SG&A
1.3M
-64.7%
3.6M
5.6M
+281.7%
1.5M
Operating Income
-1278000
+64.7%
-3618000
-3980000
-170.6%
-1471000
EBITDA
-1144000
+68.4%
-3618000
-341.8%
1.5M
+149.4%
-3028000
-349.3%
-674000
Net Income
-1247000
-119.7%
6.3M
-4753000
+36.4%
-7475000
EPS (Basic)
$-0.92
-118.4%
$5.01
$-4.83
+65.9%
$-14.15
EPS (Diluted)
$-0.92
-118.4%
$5.01
$-4.83
+65.9%
$-14.15
Shares (Diluted)
1.4M
+6.8%
1.3M
+20.1%
1.1M
+6.9%
984.9K
+86.4%
528.4K
DNA X (SONM) — Financials